| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
|
Tsuji, Daiki
|
|
|
87 |
1 |
p. 73-83
|
artikel
|
| 2 |
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib
|
Wang, Chenxiang
|
|
|
87 |
1 |
p. 43-52
|
artikel
|
| 3 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma
|
Murray Stewart, Tracy
|
|
|
87 |
1 |
p. 135-144
|
artikel
|
| 4 |
Artemisinin-type drugs for the treatment of hematological malignancies
|
Mancuso, R. I.
|
|
|
87 |
1 |
p. 1-22
|
artikel
|
| 5 |
Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses
|
Ozaki, Yoshinao
|
|
|
87 |
1 |
p. 145
|
artikel
|
| 6 |
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
|
Kitano, Shigehisa
|
|
|
87 |
1 |
p. 53-64
|
artikel
|
| 7 |
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
|
Fudio, Salvador
|
|
|
87 |
1 |
p. 113-124
|
artikel
|
| 8 |
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients
|
Macchini, Marina
|
|
|
87 |
1 |
p. 95-101
|
artikel
|
| 9 |
Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin
|
Xu, Yulin
|
|
|
87 |
1 |
p. 85-93
|
artikel
|
| 10 |
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
|
Han, Fei-fei
|
|
|
87 |
1 |
p. 103-112
|
artikel
|
| 11 |
MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma
|
Yang, Long
|
|
|
87 |
1 |
p. 125-134
|
artikel
|
| 12 |
Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
|
Sai, Satoshi
|
|
|
87 |
1 |
p. 65-71
|
artikel
|
| 13 |
Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin
|
Taflin, Helena
|
|
|
87 |
1 |
p. 31-41
|
artikel
|
| 14 |
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs
|
Mittapalli, Rajendar K.
|
|
|
87 |
1 |
p. 23-30
|
artikel
|
Tijdschrift beschrijving